Stock ADVANCED ACCELERATOR APPLICATION SA(ADR)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Advanced Accelerator Application SA(ADR)

Equities

US00790T1007

End-of-day quote Nasdaq
Other stock markets
- - Intraday chart for Advanced Accelerator Application SA(ADR)
2017 Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion RE
2017 Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
GL
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
GL
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
GL
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
GL
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer
GL
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
GL
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
GL
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
GL
Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis
GL
Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
GL
CORRECTING and REPLACING -- Advanced Accelerator Applications S.A.
GL
Advanced Accelerator Application : Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera®)
PU
Advanced Accelerator Application : Applications and FUJIFILM RI Pharma, Co., LTD Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera®)
PU
Advanced Accelerator Applications and FUJIFILM RI Pharma, Co., LTD Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera®)
GL
Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017
GL
Advanced Accelerator Application : Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)
PU
Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)
GL
Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA
GL
Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
GL
Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Advanced Accelerator Application SA(ADR)
  5. Press Releases